How FDA-Cleared AI Smart Comfort Personalization At ResMed (RMD) Has Changed Its Investment Story

• In December 2025, ResMed announced it had received U.S. FDA clearance for Smart Comfort, an AI-enabled feature that uses more than 100 million nights of de-identified sleep data to recommend personalized comfort settings for new AirSense 11 CPAP users via the myAir app, with a phased U.S. rollout planned from early 2026.
• This marks the first FDA-cleared AI device focused on individualizing CPAP comfort to support obstructive sleep apnea adherence, while leaving core prescription therapy settings unchanged.
• We’ll now explore how FDA-cleared AI-driven Smart Comfort personalization could influence ResMed’s investment narrative around digital health and adherence.

Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.

ResMed Investment Narrative Recap

To own ResMed, you need to believe in the long-term value of treating sleep apnea at scale and the company’s ability to pair devices with sticky digital tools. The Smart Comfort FDA clearance reinforces the digital health and adherence story, but it does not materially change near term catalysts or the key risk of reimbursement pressure and pricing headwinds, especially if competitive bidding tightens again.

The Smart Comfort news connects most directly with ResMed’s push into cloud-connected, AI-enhanced therapy platforms such as myAir and AirView. That direction already sits at the heart of a key catalyst: growing higher margin, recurring digital health and software engagement that could help offset risks from hardware commoditization and intensifying device competition.

However, even with AI-driven comfort features, investors still need to watch the risk that payer cost containment and potential changes to reimbursement could...

Read the full narrative on ResMed (it's free!)

ResMed's narrative projects $6.4 billion revenue and $1.9 billion earnings by 2028. This requires 7.8% yearly revenue growth and about a $0.5 billion earnings increase from $1.4 billion today.

Uncover how ResMed's forecasts yield a $295.13 fair value, a 17% upside to its current price.

Exploring Other Perspectives

Seven members of the Simply Wall St Community currently see ResMed’s fair value between US$193.80 and US$295.13, highlighting very wide dispersion in expectations. As you weigh those views, keep in mind how much the investment case now rests on ResMed turning its connected software and AI features into sustained adherence and usage that matter for long term performance.

Explore 7 other fair value estimates on ResMed - why the stock might be worth as much as 17% more than the current price!

Build Your Own ResMed Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your ResMed research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free ResMed research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ResMed's overall financial health at a glance.

Seeking Other Investments?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• These 11 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com